Publications by authors named "I Melamed"
Article Synopsis
- Traumatic brain injury (TBI) is a leading cause of death and disability in young individuals, posing significant public health and economic issues, with current treatment options being inadequate.
- This study utilizes a rat model to investigate the disruption of the blood-brain barrier (BBB) using two assessment markers, focusing on understanding the brain dysfunction that occurs after TBI.
- The research introduced a new method for evaluating BBB permeability by comparing it to traditional neuroimaging and proved effective, revealing different patterns of BBB disruption over time, with accurate sensitivity results.
Introduction: Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) is characterized by abrupt onset of obsessive-compulsive disorder or eating restriction along with the abrupt onset of other co-occurring symptoms (tics, behavioral and cognitive regression, ). PANS is thought to be a post-infectious immunopsychiatric disorder, although as with most post-infectious disorders, it is challenging to establish a causal relationship with proposed infectious triggers. Intravenous immunoglobulin (IVIG) can modulate inflammation and support the elimination of infection and has been used for treatment of many post-infectious inflammatory disorders and autoimmune conditions.
View Article and Find Full Text PDFArticle Synopsis
- - Surgical decompression is typically recommended for treating nonfunctioning pituitary macroadenomas (NFPMAs) that cause visual impairment and other symptoms, but even asymptomatic patients may face increased health issues if they opt for conservative treatment.
- - A study of 55 patients who were conservatively treated for NFPMAs revealed that many developed new symptoms, including headaches, hypertension, and hypopituitarism, along with higher rates of emergency department visits.
- - The findings indicate that early surgical intervention for NFPMAs could potentially reduce the risk of developing additional health problems and enhance overall well-being for these patients.
Article Synopsis
- * Results showed that both doses of sebetralstat provided significantly quicker relief from symptoms and attack severity compared to the placebo, with median times to relief around 1.6-1.8 hours versus over 6 hours for placebo.
- * The trial included 136 participants who treated 264 attacks, demonstrating that sebetralstat could potentially offer a more convenient oral alternative to current parenteral treatments for hereditary angioedema.